JIA in 2011: New takes on categorization and treatment

Nature Reviews Rheumatology

Volumn 8, Issue 2, 2012, Pages 67-68

  Martini, Alberto ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; CANAKINUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; RILONACEPT; SALAZOSULFAPYRIDINE; TOCILIZUMAB;

COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DRUG COST; DRUG EFFICACY; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MONOTHERAPY; ONSET AGE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

ADOLESCENT; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; DRUG THERAPY, COMBINATION; HUMANS;

EID: 84856600632     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2011.198     Document Type: Review

References (10)

1. Petty, R. E. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 31, 390-392 (2004). (Pubitemid 38160763)
2. Martini, A. Are the number of joints involved or the presence of psoriasis still useful tools to identify homogeneous disease entities in juvenile idiopathic arthritis? J. Rheumatol. 30, 1900-1903 (2003). (Pubitemid 37075533)
3. Ravelli, A. et al. Antinuclear antibody-positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. Arthritis Rheum. 63, 267-275 (2011).
4. Barnes, M. G. et al. Biologic similarities based on age at onset in oligoarticular and polyarticular subtypes of juvenile idiopathic arthritis. Arthritis Rheum. 62, 3249-3258 (2010).
5. Hirschfeld, S. & Saint-Raymond, A. Pediatric regulatory initiatives. Handb. Exp. Pharmacol. 205, 245-268 (2011).
6. Beukelman, T. et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res. (Hoboken) 63, 465-482 (2011).
7. Hashkes, P. J. Pediatric rheumatology: strengths and challenges of a new guide for treating JIA. Nat. Rev. Rheumatol. 7, 377-378 (2011).
8. Sawhney, S. & Magalhães, C. S. Paediatric rheumatology-a global perspective. Best Pract. Res. Clin. Rheumatol. 20, 201-221 (2006).
9. Ma, M. H., Kingsley, G. H. & Scott, D. L. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Rheumatology (Oxford) 49, 91-98 (2010).
10. Tynjälä, P. et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann. Rheum. Dis. 70, 1605-1612 (2011).